Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy.


Journal

Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941

Informations de publication

Date de publication:
03 2019
Historique:
entrez: 16 3 2019
pubmed: 16 3 2019
medline: 28 1 2020
Statut: ppublish

Résumé

Background Variants in the cardiomyocyte-specific RNA splicing factor RBM20 have been linked to familial cardiomyopathy, but the causative genetic architecture and clinical consequences of this disease are incompletely defined. Methods and Results To define the genetic architecture of RBM20 cardiomyopathy, we first established a database of RBM20 variants associated with cardiomyopathy and compared these to variants observed in the general population with respect to their location in the RBM20 coding transcript. We identified 2 regions significantly enriched for cardiomyopathy-associated variants in exons 9 and 11. We then assembled a registry of 74 patients with RBM20 variants from 8 institutions across the world (44 index cases and 30 from cascade testing). This RBM20 patient registry revealed highly prevalent family history of sudden cardiac death (51%) and cardiomyopathy (72%) among index cases and a high prevalence of composite arrhythmias (including atrial fibrillation, nonsustained ventricular tachycardia, implantable cardiac defibrillator discharge, and sudden cardiac arrest, 43%). Patients harboring variants in cardiomyopathy-enriched regions identified by our variant database analysis were enriched for these findings. Further, these characteristics were more prevalent in the RBM20 registry than in large cohorts of patients with dilated cardiomyopathy and TTNtv cardiomyopathy and not significantly different from a cohort of patients with LMNA-associated cardiomyopathy. Conclusions Our data establish RBM20 cardiomyopathy as a highly penetrant and arrhythmogenic cardiomyopathy. These findings underline the importance of arrhythmia surveillance and family screening in this disease and represent the first step in defining the genetic architecture of RBM20 disease causality on a population level.

Identifiants

pubmed: 30871351
doi: 10.1161/CIRCHEARTFAILURE.118.005371
pmc: PMC6422044
mid: NIHMS1518506
doi:

Substances chimiques

RNA-Binding Proteins 0
ribonucleic acid binding motif protein 20, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e005371

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL147064
Pays : United States
Organisme : NHGRI NIH HHS
ID : P01 HG000205
Pays : United States
Organisme : NHLBI NIH HHS
ID : F32 HL134233
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL069071
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL105993
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

J Clin Invest. 2014 Aug;124(8):3419-30
pubmed: 24960161
J Mol Cell Cardiol. 2017 Dec;113:9-21
pubmed: 28941705
JAMA. 2013 Mar 6;309(9):896-908
pubmed: 23462786
Clin Transl Sci. 2016 Jun;9(3):158-67
pubmed: 27105042
Cardiovasc Res. 2016 Oct;112(1):452-63
pubmed: 27496873
Genetics. 2005 Oct;171(2):783-90
pubmed: 15956674
Hum Mol Genet. 2016 Jan 15;25(2):254-65
pubmed: 26604136
Circulation. 2013 Oct 15;128(16):1810-52
pubmed: 23741057
Eur Heart J. 2017 Dec 7;38(46):3449-3460
pubmed: 29029073
Heart. 2017 Jun;103(12):901-909
pubmed: 28237968
Circ Cardiovasc Genet. 2016 Oct;9(5):419-425
pubmed: 27625338
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):6701-6
pubmed: 27247418
J Am Coll Cardiol. 2009 Sep 1;54(10):930-41
pubmed: 19712804
J Am Coll Cardiol. 2003 May 7;41(9):1561-7
pubmed: 12742298
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Nucleic Acids Res. 2013 Feb 1;41(4):2659-72
pubmed: 23307558
Am Heart J. 2008 Jul;156(1):161-9
pubmed: 18585512
Circulation. 2018 Sep 25;138(13):1330-1342
pubmed: 29650543
Circulation. 2017 Jul 11;136(2):215-231
pubmed: 28696268
Biostatistics. 2012 Jul;13(3):523-38
pubmed: 22003245
Clin Transl Sci. 2010 Jun;3(3):90-7
pubmed: 20590677
Nat Med. 2012 May;18(5):766-73
pubmed: 22466703
J Am Coll Cardiol. 2017 Oct 31;70(18):2264-2274
pubmed: 29073955
Heart Rhythm. 2018 Oct;15(10):e190-e252
pubmed: 29097320
J Am Coll Cardiol. 2016 Nov 29;68(21):2299-2307
pubmed: 27884249

Auteurs

Victoria N Parikh (VN)

Division of Cardiovascular Medicine, Department of Medicine (V.N.P., C.C., C.R., M.T.W., E.A.A.), Stanford University School of Medicine, CA.

Colleen Caleshu (C)

Division of Cardiovascular Medicine, Department of Medicine (V.N.P., C.C., C.R., M.T.W., E.A.A.), Stanford University School of Medicine, CA.

Chloe Reuter (C)

Division of Cardiovascular Medicine, Department of Medicine (V.N.P., C.C., C.R., M.T.W., E.A.A.), Stanford University School of Medicine, CA.

Laura C Lazzeroni (LC)

Department of Psychiatry and Behavioral Sciences (L.C.L.), Stanford University School of Medicine, CA.
Department of Biomedical Data Science (L.C.L.), Stanford University School of Medicine, CA.

Jodie Ingles (J)

Department of Cardiology, Royal Prince Alfred Hospital and Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, University of Sydney, New South Wales, Australia (J.I., C.S.).

John Garcia (J)

Invitae, Inc, San Francisco, CA (J.G., R.N.).

Kristen McCaleb (K)

Genomic Health, Inc, Redwood City, CA (K.M.).

Tolulope Adesiyun (T)

Johns Hopkins School of Medicine, Baltimore, MD (T.A.).

Farbod Sedaghat-Hamedani (F)

Institute for Cardiomyopathies, University Hospital Heidelberg, German Center for Cardiovascular Research (F.S.-H., B.M.).

Saurabh Kumar (S)

Brigham and Women's Hospital, Partners Health Care and Harvard Medical School, Boston, MA (S.K., N.K.L.).

Sharon Graw (S)

Cardiovascular Institute, University of Colorado Anschutz Medical Campus, Aurora (S.G., M.R.G.T., L.M.).

Marta Gigli (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).

Davide Stolfo (D)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).

Matteo Dal Ferro (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).

Alexander Y Ing (AY)

Laboratory of Molecular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.Y.I., B.F.).

Robert Nussbaum (R)

Invitae, Inc, San Francisco, CA (J.G., R.N.).

Birgit Funke (B)

Laboratory of Molecular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.Y.I., B.F.).

Matthew T Wheeler (MT)

Division of Cardiovascular Medicine, Department of Medicine (V.N.P., C.C., C.R., M.T.W., E.A.A.), Stanford University School of Medicine, CA.

Ray E Hershberger (RE)

Division of Human Genetics, Department of Medicine (R.E.H.), The Ohio State University College of Medicine, Columbus.
Division of Cardiovascular Medicine, Department of Medicine (R.E.H.), The Ohio State University College of Medicine, Columbus.

Stuart Cook (S)

National Heart Lung Institute, Imperial College London, UK and National Heart Centre, Singapore (S.C.).

Lars M Steinmetz (LM)

Department of Genetics (L.M.S., B.M., E.A.A.), Stanford University School of Medicine, CA.

Neal K Lakdawala (NK)

Brigham and Women's Hospital, Partners Health Care and Harvard Medical School, Boston, MA (S.K., N.K.L.).

Matthew R G Taylor (MRG)

Cardiovascular Institute, University of Colorado Anschutz Medical Campus, Aurora (S.G., M.R.G.T., L.M.).

Luisa Mestroni (L)

Cardiovascular Institute, University of Colorado Anschutz Medical Campus, Aurora (S.G., M.R.G.T., L.M.).

Marco Merlo (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).

Gianfranco Sinagra (G)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).

Christopher Semsarian (C)

Department of Cardiology, Royal Prince Alfred Hospital and Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, University of Sydney, New South Wales, Australia (J.I., C.S.).

Benjamin Meder (B)

Department of Genetics (L.M.S., B.M., E.A.A.), Stanford University School of Medicine, CA.
Institute for Cardiomyopathies, University Hospital Heidelberg, German Center for Cardiovascular Research (F.S.-H., B.M.).

Daniel P Judge (DP)

Department of Medicine, Medical University of South Carolina, Charleston (D.P.J.).

Euan Ashley (E)

Division of Cardiovascular Medicine, Department of Medicine (V.N.P., C.C., C.R., M.T.W., E.A.A.), Stanford University School of Medicine, CA.
Department of Genetics (L.M.S., B.M., E.A.A.), Stanford University School of Medicine, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH